Natalia C Llarena1, Samantha L Estevez1, Susan L Tucker2, Jacqueline S Jeruss3,4. 1. Northwestern University Feinberg School of Medicine, Chicago, IL. 2. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX. 3. Department of Surgery, University of Michigan, Ann Arbor, MI. 4. Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Abstract
BACKGROUND: Adjuvant tamoxifen reduces breast cancer recurrence risk and mortality; however, initiation and treatment persistence are poor for younger patients. We hypothesized that a unique set of factors, including fertility concerns, would contribute to the poor tamoxifen use among premenopausal patients. METHODS: From 2007 to 2012, 515 premenopausal patients younger than age 45 years, with stage 0 to III hormone receptor-positive breast cancer, for whom tamoxifen was recommended, were identified. Clinical and pathologic tumor characteristics, treatment regimens, and fertility concerns were recorded. Clinical factors associated with tamoxifen noninitiation and discontinuation were identified using univariate and multivariable analysis. After the recommendation for tamoxifen, patient reasons for tamoxifen noninitiation or discontinuation were also documented. All statistical tests were two-sided. RESULTS: Based on multivariable analysis, fertility concerns were statistically associated with both noninitiation (odds ratio = 5.04, 95% confidence interval (CI) = 2.29 to 11.07) and early discontinuation (hazard ratio = 1.78, 95% CI = 1.09 to 3.38) of tamoxifen. Other independent predictors of noninitiation included a diagnosis of ductal carcinoma in situ, declining radiation, and not receiving chemotherapy (stage I-III). Additionally, smoking and not receiving radiation therapy were statistically significant predictors of early withdrawal from therapy. Primary patient reasons for noninitiation and early discontinuation included concerns about side effects and fertility. CONCLUSION: This study provided insight into factors associated with tamoxifen use for reproductive-aged breast cancer survivors, with a new focus on fertility. Fertility concerns negatively impacted tamoxifen initiation and continuation among premenopausal patients. Interventions to optimize treatment initiation and persistence for young cancer patients should include access to fertility preservation options.
BACKGROUND: Adjuvant tamoxifen reduces breast cancer recurrence risk and mortality; however, initiation and treatment persistence are poor for younger patients. We hypothesized that a unique set of factors, including fertility concerns, would contribute to the poor tamoxifen use among premenopausal patients. METHODS: From 2007 to 2012, 515 premenopausal patients younger than age 45 years, with stage 0 to III hormone receptor-positive breast cancer, for whom tamoxifen was recommended, were identified. Clinical and pathologic tumor characteristics, treatment regimens, and fertility concerns were recorded. Clinical factors associated with tamoxifen noninitiation and discontinuation were identified using univariate and multivariable analysis. After the recommendation for tamoxifen, patient reasons for tamoxifen noninitiation or discontinuation were also documented. All statistical tests were two-sided. RESULTS: Based on multivariable analysis, fertility concerns were statistically associated with both noninitiation (odds ratio = 5.04, 95% confidence interval (CI) = 2.29 to 11.07) and early discontinuation (hazard ratio = 1.78, 95% CI = 1.09 to 3.38) of tamoxifen. Other independent predictors of noninitiation included a diagnosis of ductal carcinoma in situ, declining radiation, and not receiving chemotherapy (stage I-III). Additionally, smoking and not receiving radiation therapy were statistically significant predictors of early withdrawal from therapy. Primary patient reasons for noninitiation and early discontinuation included concerns about side effects and fertility. CONCLUSION: This study provided insight into factors associated with tamoxifen use for reproductive-aged breast cancer survivors, with a new focus on fertility. Fertility concerns negatively impacted tamoxifen initiation and continuation among premenopausal patients. Interventions to optimize treatment initiation and persistence for young cancerpatients should include access to fertility preservation options.
Authors: Anne Cooley; Laura Matthews; Stanislav Zelivianski; Ashley Hardy; Jacqueline S Jeruss Journal: Hum Reprod Date: 2011-11-10 Impact factor: 6.918
Authors: Laura Cruciani; Roberto Romero; Edi Vaisbuch; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Shali Mazaki-Tovi; Pooja Mittal; Giovanna Ogge; Francesca Gotsch; Offer Erez; Sun Kwon Kim; Zhong Dong; Percy Pacora; Ronald F Lamont; Lami Yeo; Sonia S Hassan; Gian Carlo Di Renzo Journal: J Perinat Med Date: 2010-03 Impact factor: 1.901
Authors: Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: Shoshana M Rosenberg; Keith J Petrie; Annette L Stanton; Lan Ngo; Emma Finnerty; Ann H Partridge Journal: J Natl Cancer Inst Date: 2020-05-01 Impact factor: 13.506
Authors: Lisa M Shandley; Jessica B Spencer; Amy Fothergill; Ann C Mertens; Amita Manatunga; Elisavet Paplomata; Penelope P Howards Journal: Fertil Steril Date: 2016-11-22 Impact factor: 7.329
Authors: Matteo Lambertini; Christine Campbell; José Bines; Larissa A Korde; Miguel Izquierdo; Debora Fumagalli; Lucia Del Mastro; Michail Ignatiadis; Kathleen Pritchard; Antonio C Wolff; Christian Jackisch; Istvan Lang; Michael Untch; Ian Smith; Frances Boyle; Binghe Xu; Carlos H Barrios; José Baselga; Alvaro Moreno-Aspitia; Martine Piccart; Richard D Gelber; Evandro de Azambuja Journal: J Natl Cancer Inst Date: 2019-01-01 Impact factor: 13.506
Authors: Shoshana M Rosenberg; Shari Gelber; Richard D Gelber; Ethan Krop; Larissa A Korde; Olivia Pagani; Ann H Partridge Journal: J Adolesc Young Adult Oncol Date: 2017-07-07 Impact factor: 2.223
Authors: Leah Hawkins Bressler; Jennifer E Mersereau; Chelsea Anderson; Juan L Rodriguez; M Elizabeth Hodgson; Clarice R Weinberg; Dale P Sandler; Hazel B Nichols Journal: Cancer Date: 2019-04-23 Impact factor: 6.860
Authors: Joceline V Vu; Natalia C Llarena; Samantha L Estevez; Molly B Moravek; Jacqueline S Jeruss Journal: J Surg Oncol Date: 2016-12-14 Impact factor: 3.454
Authors: Nikita M Shah; Dana M Scott; Pridvi Kandagatla; Molly B Moravek; Erin F Cobain; Monika L Burness; Jacqueline S Jeruss Journal: Ann Surg Oncol Date: 2019-01-24 Impact factor: 5.344